Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VM-1500 + raltegravir
- Development stage
- Unknown
- Lead developer
- Viriom
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
VM-1500 + raltegravir** is a pharmaceutical combination under investigation for drug-drug interaction and pharmacokinetics, primarily in the context of antiretroviral therapy. VM-1500 is an investigational compound (precise class not specified in public sources). Raltegravir is a first-in-class HIV-1 integrase inhibitor, approved for treatment of HIV infection. Raltegravir blocks the action of HIV integrase, preventing viral DNA from integrating into the host genome. The combination is being explored for possible synergistic or pharmacokinetic compatibility, particularly in healthy volunteers[1][2].
- Other names
- VM-1500 + raltegravirVM1500 + raltegravir
02
Targets
Integrase allosteric pocket (HIV)Human immunodeficiency virus type 1 reverse transcriptase
Beyond the preview
Go deeper on VM-1500 + raltegravir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VM-1500 + raltegravir.